DiaMedica Therapeutics (DMAC) Current Leases (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Current Leases of $104000.0 for Q1 2026, up 11.83% year-over-year from $93000.0 in Q1 2025, and up 845.45% quarter-over-quarter from $11000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Current Leases (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Current Leases history runs 9 years deep, the most recent figure standing at $104000.0 for Q1 2026.
- In Q1 2026, Current Leases rose 11.83% year-over-year to $104000.0; the TTM figure through Mar 2026 stood at $104000.0 (up 11.83% YoY), while the FY2025 annual figure was $11000.0, down 15.38% from the prior year.
- Current Leases for Q1 2026 stood at $104000.0, up from $11000.0 in the prior quarter.
- The five-year high for Current Leases was $104000.0 in Q1 2026, with the low at $2000.0 in Q3 2023.
- The 5-year median for Current Leases is $28000.0 (2022), against an average of $45882.4.
- The sharpest annual moves came in 2024 and 2025: Current Leases surged 4300.0% in 2024, then tumbled 85.88% in 2025.
- DiaMedica Therapeutics' Current Leases stood at $63000.0 in 2022, then gained by 26.98% to $80000.0 in 2023, then slumped by 83.75% to $13000.0 in 2024, then decreased by 15.38% to $11000.0 in 2025, then jumped by 845.45% to $104000.0 in 2026.
- Business Quant data shows DMAC's Current Leases at $104000.0 in Q1 2026, $11000.0 in Q4 2025, and $99000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 107,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 107,000.00 |
| Mar 31, 2026 | 104,000.00 |
| Dec 31, 2025 | 11,000.00 |
| Sep 30, 2025 | 99,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 88,000.00 |
| Jun 30, 2024 | 85,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 76,000.00 |
| Mar 31, 2023 | 5,000.00 |
| Dec 31, 2022 | 63,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 11,000.00 |
| Mar 31, 2022 | 28,000.00 |
| Dec 31, 2021 | 45,000.00 |
| Sep 30, 2021 | 4,000.00 |